Treatment of cutaneous sporotrichosis with terbinafine
- 1 February 1992
- journal article
- case report
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 126 (s39), 51-55
- https://doi.org/10.1111/j.1365-2133.1992.tb00011.x
Abstract
Terbinafine, an allylamine antifungal agent, has been shown to have excellent in‐vitro activity against dermatophytes. Several other fungi of importance also show in‐vitro sensitivity. Because terbinafine is fungicidal rather than fungistatic in action, its efficacy in treating such fungal infections requires evaluation. Five patients with cutaneous sporotrichosis were treated with 250 mg of terbinafine twice daily. All of the patients were cured. Overall, the clinical response was rapid. In three patients, negative culture was achieved within 8 weeks: in the other two, negative culture was obtained at 12 and 32 weeks, respectively. Terbinafine was well tolerated, although one patient developed erectile dysfunction while receiving treatment. This was completely resolved on stopping the treatment. The treatment of sporotrichosis is also reviewed in this article.Keywords
This publication has 8 references indexed in Scilit:
- Administration of potassium iodide to normal volunteers does not increase killing ofSporothrix schenckiiby their neutrophils or monocytesMedical Mycology, 1990
- Sporotrichosis in the acquired immunodeficiency syndromeJournal of the American Academy of Dermatology, 1989
- In vitro activity of terbinafineClinical and Experimental Dermatology, 1989
- Efficacies of four antifungal agents in experimental murine sporotrichosisAntimicrobial Agents and Chemotherapy, 1988
- Antifungal activity of the allylamine derivative terbinafine in vitroAntimicrobial Agents and Chemotherapy, 1987
- Pulmonary SporotrichosisMedicine, 1986
- Itraconazole therapy in lymphangitic and cutaneous sporotrichosisArchives of Dermatology, 1986
- In-vitro studies with SF 86–327, a new orally active allylamine derivativeMedical Mycology, 1985